MLTX
MoonLake ImmunotherapeuticsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.23B
P/E Ratio
—
EPS
$-3.55
Beta
1.19
52W High
$62.75
52W Low
$5.95
50-Day MA
$16.97
200-Day MA
$27.60
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a pioneering biotechnology company focused on developing innovative therapies for chronic inflammatory diseases using its proprietary drug delivery platform. The firm is currently advancing its lead product candidate, a novel interleukin-17 inhibitor, through clinical trials, aiming to provide transformative treatment solutions that could significantly enhance patient outcomes. With a strong research pipeline and strategic partnerships, MoonLake is well-positioned to impact the immunotherapy market, addressing critical unmet medical needs while creating substantial value for shareholders.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-242.22M |
| Operating Margin | 0.00% |
| Return on Equity | -60.80% |
| Return on Assets | -33.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.27 |
| Price-to-Book | 4.09 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -41.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $71.73M |
| Float | $39.23M |
| % Insiders | 10.72% |
| % Institutions | 75.49% |
Analyst Ratings
Consensus ($26.71 target)
1
Strong Buy11
Buy2
Hold2
SellData last updated: 4/8/2026